Form 4: Zentalis Pharmaceuticals Director David Johnson Acquires Restricted Stock Units

Director David Michael Johnson acquired 48,429 restricted stock units in Zentalis Pharmaceuticals, Inc. on June 21, 2024.

Summary

• On June 21, 2024, David Michael Johnson, a director of Zentalis Pharmaceuticals, Inc., acquired 48,429 shares of common stock in the form of restricted stock units.
• These restricted stock units were granted pursuant to the Issuer's Non-Employee Director Compensation Program.
• Each unit represents a contingent right to receive one share of common stock.
• The units will vest on the earlier of June 21, 2025, or the next annual meeting of the Issuer's stockholders, contingent upon Johnson's continued service on the Board of Directors.
• Following the transaction, Johnson beneficially owns 192,818 shares of Zentalis Pharmaceuticals, Inc.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of restricted stock units is a standard practice and indicates alignment of the director's interests with shareholders.

Positives

• The grant of restricted stock units aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.

Future Outlook

The director's continued service on the board is tied to the vesting of the restricted stock units, suggesting an expectation of ongoing involvement and contribution to the company.

Industry Context

Grants of restricted stock units to directors are a common practice in the pharmaceutical industry to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Director compensation packages, including grants of restricted stock units, are common in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize equity-based compensation for their directors.
• The size and vesting schedule of these grants vary depending on the company's size, performance, and compensation philosophy.

Stakeholder Impact

• The grant of restricted stock units aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit shareholder value.

Key Dates